Optimizing patient assessment in MS: NEDA and beyond


Treatment optimization and combining metrics
NEDA – new approach
NeuroSens Survey: How do you assess treatment response in practice?

The proliferation of disease-modifying therapies (DMT) in multiple sclerosis has focused attention on the need for improved measures for evaluating treatment efficacy and response. In part, this is driven by the increasing difficulty of detecting a treatment effect in clinical trials of early MS patients with minimal disease activity, as well as the need to differentiate DMTs with respect to their varying effects on clinical and radiological endpoints. In clinical practice, identifying suboptimal responders is a matter of some urgency since therapies are more likely to provide benefit in the first 2-5 years after diagnosis of CIS/MS. An early treatment effect may be the only effect, so it is important to optimize the drug regimen before the window of opportunity for effective intervention is shuttered.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page